Indivior Share Discussion Threads

[tsmith2] 22/11/2018 08:31

hovering over button, waiting to see whether they try a quick shake

[maywillow] 22/11/2018 08:31

of course this is a high risk share bot potential rewards might be substantial

Net Cash PS 0.91 p
Net Tangible Asset Value PS * -29.99 p
Net Asset Value PS -20.64 p

if the above information given by advfn is correct, the current share price ia a little overvalued but that has not stopped STANDARD LIFE and ARTEMIS INVESTING


ALL THATS NEEDED IS SUPER GOOD NEWS

[comedy] 22/11/2018 08:27

well ive bought:)

[tsmith2] 22/11/2018 08:15

When you are going to talks bullocks try being remotely correctlyCash balance at the end of Q3 2018 was $901m (FY 2017: $863m); net cash was $569m (FY 2017: $376m).

[pwhite73] 22/11/2018 08:13

dealy - Its the company's debt that makes it high risk and with the prospect of 80% reduced revenues just the day to day running of the company is put at even greater risk.

tsmith2 - The holdings announcements are meaningless. They both tell you that Artemis and Standard Life are buying for a range of funds and investments not necessarily for themselves. The buying could be shorts closing, small investments pooled buys etc.

The daily ups and downs are an internal struggle between daily traders short and long.

The real bit of next news is when Dr Reddys announce they have started selling their generic drug. The stock will plunge again.

[dealy] 21/11/2018 17:22

if the company didn't have any revenue at all it would be worth more than this

[tsmith2] 21/11/2018 16:39

Standard life picked up 1.5% to go to 13.61% yesterday too.this is getting interesting.

[tsmith2] 21/11/2018 12:41

They picked up 38.5mn shares I wonder what price yesterday

[tsmith2] 21/11/2018 12:31

Artemis picked up 5.3% of share capital yesterday? Who dumped.?

[sarkasm] 21/11/2018 11:40

PROACTIVEINVESTORS

Indivior slumps as US court lifts injunction stopping rival from selling Suboxone copycat
10:45 21 Nov 2018
Indivior is still going through the courts to try to prove that Dr Reddy’s drug breaches its patents, but the lifting of the injunction means the Indian drugs giant can sell its version while a decision is made
suboxone drug
A final patent hearing is due to take place towards the end of this year or early in 2019

Indivior PLC (LON:INDV) shares have slumped once again after the US Court of Appeals decided to lift a preliminary injunction which had been stopping a rival drugmaker from selling its generic version of Suboxone – Indivior’s blockbuster opioid addiction treatment.

Analysts said they were surprised by the decision, which opens the door for Indian generics giant Dr Reddy’s to start selling its copycat drug again, albeit on an ‘at-risk basis’, meaning it can do so while litigation is still ongoing.
READ: Indivior's profits tumble as Suboxone copycat eats into market share

The injunction had prevented Dr Reddy’s from supplying its rival product to doctors and clinics while a US court decides whether or not it breaches any of Indivior’s patents. That case is still ongoing, with a final hearing expected to take place later this year or in early 2019.

Indivior is keeping its much-reduced net revenue and net income guidance in place for the time being, until it knows for sure when Dr Reddy’s will re-start sales.

“Should generic buprenorphine/naloxone sublingual film enter the market in 2018, the result would most likely be a rapid and material loss of market share for Suboxone,” read a gloomy Indivior statement.

“A material loss in market share in the US would have a significant adverse impact on the company's revenues, profitability and cash flows.”
More generics on the way

Mid-tier Canadian investment bank RBC Capital expects Dr Reddy’s will indeed launch ‘at risk’ later this year, although it thinks that might be the least of the company’s worries.

“We assume a launch of DR's generic before year-end, with follow-on launches from Mylan, Parr and Alvogen (once approved) but also the authorised generic from Sando,” analysts said in a note to clients.

Indivior knew it was in a spot of trouble with Suboxone so it developed Sublocade, a once-monthly injection which it hoped doctors would switch to, easing some of the pressure.

RBC analysts recognise the need for Sublocade to pick up some of the slack, which they expect it will further down the line, although they are more cautious near-term.

Given the likely sharp decline in Suboxone revenues and doubts over Sublocade’s ability to fill the void, RBC downgraded the stock to ‘perform’; (from ‘outperform217;) and slashed its price target to 130p (from 350p).

Indivior shares fell 12.4% to 96.3p on Wednesday morning. Less than six months ago they were worth almost 500p.

[pwhite73] 21/11/2018 11:39

They talked of revenues falling up to 80% as a result of the judgement. The company cannot survive in its current form. Loans, staff and other drugs cannot be funded with such a drastic cut in revenues. The only hope now is a takeover for the commercial bits. Investors must be careful because the stock can easily be suspended pending clarification of its financial position.

[tsmith2] 21/11/2018 11:12

Trying to rise now.Could be a good afternoon. Watching closely.

[gregmorg] 21/11/2018 10:17

Yes BTG Bid gave quite a nice uplift to the start of yesterday and maybe relaxed the stomach muscles ready for the Indivior boot into the same region!

I now have no idea on this one. Will adopt the usual position of head down and inertia and see whether we have something or nothing. Not into religious investing I am afraid ,Steeplejack, although the old market religious investing comments in moments of adversity "And on the third day etc etc had appeal! Maybe that was an antidote to "avoiding trying to catch falling knives"!

[tsmith2] 21/11/2018 09:09

£1 seems to be resistance. but base forming possibly. Watching v carefully to go long

[tsmith2] 21/11/2018 08:22

the odd deramp etc is fine but plain silly comments deserve a put down

[tsmith2] 21/11/2018 08:21

lol. cretin alert.

[pwhite73] 21/11/2018 08:17

The company has a value of £800m. You can't touch this until the market cap is about £100m. At this level it may attract a buyer.

[tsmith2] 21/11/2018 08:14

What I want before jumping in:reversal volume may well have reversed

[tsmith2] 21/11/2018 08:12

Short positions 3.5-4% or so.a lot of shorts to close.Watching from sidelines

[kirk 6] 21/11/2018 08:11

Prepare for a major bounce in at 98p

[pwhite73] 21/11/2018 08:05

PWhite731 Oct '18 - 22:32 - 452 of 491 Edit
0 0 0
The writing is on the wall for this company. The share price was trading at 490p in June 2018. There are a number of problems here.

1. The opioid addiction market is too competitive and relatively easy to enter.
2. The injunction against Dr Reddy is only temporary.
3. Donald Trump and the State Department are soon to announce their own nationwide programme to combat opioid addiction in the US.

The shares can be traded as it bounces off the bottom but because of the share price you need lots of upfront capital to make any decent money. Those who think the share price is about to mount a recovery are mistaken. When the next set of adverse news is released it will plunge again

[pwhite73] 21/11/2018 08:05

PWhite731 Oct '18 - 22:32 - 452 of 491 Edit
0 0 0
The writing is on the wall for this company. The share price was trading at 490p in June 2018. There are a number of problems here.

1. The opioid addiction market is too competitive and relatively easy to enter.
2. The injunction against Dr Reddy is only temporary.
3. Donald Trump and the State Department are soon to announce their own nationwide programme to combat opioid addiction in the US.

The shares can be traded as it bounces off the bottom but because of the share price you need lots of upfront capital to make any decent money. Those who think the share price is about to mount a recovery are mistaken. When the next set of adverse news is released it will plunge again

[parvez] 21/11/2018 07:41

where does this open today?